Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

  • Principal Investigator: Sarah Bailey
  • 1 September 2021 to 28 February 2022
  • Project No: 511
  • Funding round: FR1

Men from black and minority ethnic backgrounds are more likely to develop prostate cancer and more likely to get very ill or die from their cancer, compared to the white majority. Finding ways to spot prostate cancer in these men earlier is one way that this gap can be reduced.

General Practitioners (GPs) can use a prostate specific antigen (PSA) test, which is measured with a standard blood test, when they see men with symptoms that might relate to a prostate cancer. If the PSA is high, this might indicate the man has a prostate cancer that has not been picked up yet, and they are usually sent to hospital for more tests. This could be an MRI scan or a prostate biopsy.

Studies have found that men from different ethnic groups have different ‘normal’ and ‘abnormal’ levels of PSA. These differences are not currently considered in guidance for doctors when trying to understand the results of a PSA test.

Our team has studied blood tests and their usefulness in finding cancer extensively. In this study, we want to find out how best to use the PSA test to help GPs find prostate cancer earlier in people from minority ethnic backgrounds.


Tanimola Martins


Amount awarded: £30,506

Projects by themes

We have grouped projects under the five SPCR themes in this document

Evidence synthesis working group

The collaboration will be conducting 18 high impact systematic reviews, under four workstreams.